השוואת שיטות
סקרו את השיטות שבחרתם זו לצד זו; שורות שבהן יש הבדל מודגשות.
| מחקר שלב IV מותאם סיכון× | משקולות הסתברות הפוכות (IPW / IPTW)× | |
|---|---|---|
| תחום≠ | אפידמיולוגיה | הסקה סיבתית |
| משפחה≠ | Process / pipeline | Regression model |
| שנת המקור≠ | 1990s–2000s (formalized with ICH E2E and EMA PASS guidelines) | 2000 |
| הוגה השיטה≠ | Regulatory and pharmacoepidemiology community (ICH, EMA, FDA frameworks) | Robins, Hernán & Brumback |
| סוג≠ | Observational / quasi-experimental clinical study design | Causal inference weighting estimator |
| מקור מכונן≠ | Strom, B. L. (Ed.). (2005). Pharmacoepidemiology (4th ed.). John Wiley & Sons. ISBN: 978-0470863107 | Robins, J. M., Hernán, M. A., & Brumback, B. (2000). Marginal Structural Models and Causal Inference in Epidemiology. Epidemiology, 11(5), 550-560. DOI ↗ |
| כינויים≠ | risk-adjusted post-marketing surveillance study, adjusted Phase IV trial, risk-stratified post-authorization study, PASS with risk adjustment | IPW, IPTW, inverse probability of treatment weighting, marginal structural model weighting |
| קשורות≠ | 3 | 5 |
| תקציר≠ | A risk-adjusted Phase IV study is an observational or semi-experimental post-marketing study conducted after a drug or device has received regulatory approval. It uses statistical risk-adjustment techniques — such as propensity score matching, inverse probability weighting, or multivariable regression — to control for confounding by indication and baseline patient differences, thereby producing more credible safety, effectiveness, and utilization estimates than unadjusted real-world analyses. | Inverse Probability Weighting is a causal-inference method that assigns each observation a weight equal to the inverse of its probability of receiving the treatment it actually received. Introduced by Robins, Hernán and Brumback (2000) for marginal structural models, it builds a pseudo-population in which treatment is independent of measured confounders, balancing selection bias. |
| ScholarGateמערך נתונים ↗ |
|
|